Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically
relevant tumor-targeting immune responses, which critically rely on the antigenicity of …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Research on tumor immunotherapy has made tremendous progress in the past decades,
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …

Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …

Dendritic cells (DCs) are key regulators of immune responses that operate at the interface
between innate and adaptive immunity, and defects in DC functions contribute to the …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Radiation therapy (RT) can induce an immunogenic variant of regulated cell death that can
initiate clinically relevant tumor-targeting immune responses. Immunogenic cell death (ICD) …

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer
management have been well documented after more than twenty-five years of …

Ovarian cancer (OC) is one of the most lethal malignant gynecologic tumors, characterized
by an uncertain presentation and poor outcomes. With or without neoadjuvant …